Product Details
| Product Name:
Zavondemstat |
CAS No.:
1851412-93-5 |
| Purity:
99.71% |
Supply Ability:
10g |
| Release date:
2026/06/10 |
Product Introduction
Bioactivity
| Name | Zavondemstat |
| Description | Zavondemstat (QC8222) is an orally active, selective inhibitor of the histone lysine demethylase 4 (KDM4) family, with an IC?? of ≤ 0.08 μM against human KDM4A–D and a K?? of 0.52 μM against human KDM4C. Zavondemstat activates tumor suppressor genes, induces apoptosis, causes S-phase cell cycle arrest, and inhibits cancer cell proliferation. In in vivo studies, Zavondemstat inhibits tumor growth and induces tumor regression. Zavondemstat can be used in cancer research. |
| In vitro | Methods: MDA-MB-231 cells were treated with TACH101 (0.01, 0.1 μmol/L) and cultured for 48 h and 72 h; cell cycle analysis was performed using PI staining and flow cytometry.
Results: Zavondemstat induces S-phase cell cycle arrest in MDA-MB-231 cells. [1]
Methods: Jurkat, MDA-MB-231, KYSE-150, MM.1s, HL-60, HT-29, MCF-7, LOUCY, and IMR-90 cell lines were treated with Zavondemstat (0.0005–10 μmol/L) and cultured for 7 days; cell proliferation was assessed using the BrdU incorporation assay, MTS assay, and CellTiter-Glo assay.
Results: Zavondemstat potently inhibited the proliferation of multiple cancer cell lines, with IC?? values ranging from 0.0027 to 0.037 μM, while exhibiting lower activity against normal IMR-90 fibroblasts [1]. |
| In vivo | Methods: In a colorectal cancer PDX model in NSG mice, following successful tumor implantation, Zavondemstat (TACH101) (10, 20 mg/kg) was administered orally once daily for 3 weeks.
Results: Zavondemstat (TACH101) inhibited tumor growth in a dose-dependent manner. [1]
Methods: A CDX model of esophageal squamous cell carcinoma was established in nude mice. Following successful implantation, Zavondemstat (TACH101) (10, 15, 20 mg/kg) was administered orally once daily for 3 weeks.
Results: Zavondemstat (TACH101) effectively inhibited tumor growth in a dose-dependent manner. [1] |
| Storage | Store under nitrogen,Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 7.25 mg/mL (16.8 mM), Sonication and heating are recommended.
|
| Keywords | Zavondemstat | TACH-101 | TACH101 | TACH 101 | QC-8222 | QC8222 | QC 8222 | KDM4 | HistoneDemethylase | Histone Demethylase |
| Inhibitors Related | LSD1-IN-24 | Procaine | TFMB-(R)-2-HG | GSK-LSD1 dihydrochloride | GSK-J4 | FY-21 | Phenelzine sulfate | Pulrodemstat HCl | Daminozide | AS8351 | Procaine hydrochloride | Eicosapentaenoic Acid |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Anti-Breast Cancer Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States